TY - JOUR
TI - Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data
from Two Nonendemic Regions
AU - Economopoulou, Panagiota
AU - Pantazopoulos, Anastasios
AU - Spathis, Aris
AU - and Kotsantis, Ioannis
AU - Kyriazoglou, Anastasios
AU - Kavourakis,
AU - George
AU - Zakopoulou, Roubini
AU - Chatzidakis, Ioannis
AU - Anastasiou,
AU - Maria
AU - Prevezanou, Maria
AU - Resteghini, Carlo
AU - Licitra, Lisa and
AU - Bergamini, Cristiana
AU - Colombo, Elena
AU - Caspani, Francesca and
AU - Denaro, Nerina
AU - Vecchio, Stefania
AU - Bonomo, Pierluigi
AU - Cossu
AU - Rocca, Maria
AU - Bertolini, Federica
AU - Ferrari, Daris
AU - Psyrri,
AU - Amanda
AU - Bossi, Paolo
JO - Cell Stem Cell
PY - 2022
VL - 11
TODO - 1
SP - null
PB - MDPI
SN - 1934-5909
TODO - 10.3390/cells11010032
TODO - immunotherapy; nasopharyngeal cancer; EBV DNA; nonendemic region
TODO - Background: nasopharyngeal carcinoma (NPC) is a complex disease entity
that mainly predominates in endemic regions. Real-world data with
immunotherapy from nonendemic regions are limited. Methods: we collected
data from patients with recurrent/metastatic (R/M) NPC treated at a
center in Greece and 8 centers in Italy. Between 2016 and 2021, 46
patients who were treated with at least one cycle of immune checkpoint
inhibitors (ICI) were identified. Herein, we present our results and a
review of the literature. Results: assessment of response was available
in 42 patients. Overall, 11 patients responded to immunotherapy (Overall
Response Rate-ORR 26.2%). Three patients had complete response (CR),
and 8 patients had partial response (PR). Disease control rate (DCR) was
61.9%. Median Progression Free Survival (PFS) was 5.6 months and median
Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS
and OS as compared to that of nonresponders. A lower probability of
responding to ICI was shown in patients with more than three metastatic
sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039)
or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV
DNA levels was found to be statistically significant associated with
best response to ICI (p = 0.049). Safety was manageable. Conclusions:
among 46 patients with R/M NPC treated with immunotherapy in two
nonendemic regions, ORR was 26.2% and durable responses were observed.
Low disease burden could serve as a biomarker for response to ICI.
ER -